HTDs and JSCs: Strategies to maximize impact and value

January 2025 sees the implementation of the Health Technology Assessment Regulation (HTAR) developed to reduce the admin burden and equalize access of important medicines to EU patients through a collaborative framework. New concepts such as JSC and JCA act as guidance for developers but are often complex and highly competitive. Discover more about the process, including:

Benefits of Joint Scientific Consultations (JSCs)
Importance of facilitating early dialogue with regulatory/EU HTA bodies
Strategic considerations before applying for a JSC
Competitive nature of securing JSC slots
Advice on preparation, reviewing guidance and aligning cross-functionally
Valuable insights from the JSC pilot

Read the Blog

Your company email address

Please select your industry: (max 1)
Yes, I would like to be contacted by an IQVIA expert

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow IQVIA to store and process the information submitted to provide you the content requested. They are subject to IQVIA Terms and Conditions.

Please complete all required fields to access the content!

Future-Ready Pharmacovigilance: Integrating AI With FDA's EDSTP Guidelines

Join IQVIA’s esteemed panel of experts for an in-depth discussion on how AI can meet and exceed these new expectations. This webinar delves into the intersection of regulatory frameworks and technological innovation, offering insights into the future of PV and how organizations can navigate this transformative field. Key takeaways include:

Accelerating Biologics Development With Strategies For Success

The biologics market is growing rapidly, unlocking exciting opportunities but also presenting significant challenges. Developers are undergoing pressure to accelerate the delivery of innovative therapies while addressing complex regulatory demands, navigating demanding clinical trial phases, efficiently scaling production, and maintaining quality. In this webinar, industry experts will share practical strategies and real-world examples to help you navigate these challenges. Key takeaways:

A New Era of Participant Payment Services

Financial burdens are cited as one of the main barriers to clinical trial recruitment and retention, with traditional methods proving unreliable, complicated and slow. For trial sites and sponsors, the administration burden can be overwhelming, especially on a global scale. Discover how IQVIA’s Participant Payment service is transforming the participant payment landscape, simplifying the process and driving clinical trial success, by offering: